BriaCell Files New Provisional Patent Application for Antibody-Based Treatment of Infectious Diseases
April 21 2020 - 5:30AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, announces that it has filed a provisional patent
application with the U.S. Patent and Trademark Office (USPTO)
outlining the development and use of certain antibodies for the
treatment of cancer and infectious diseases. The infectious
diseases include Coronavirus Disease 2019 (COVID-19) caused by the
SARS-CoV-2 virus.
The patent application, entitled
“COMPUTER-GUIDED DESIGN OF ANTIBODIES INCLUDING NEUTRALIZING
SARS-CoV-2 BINDING AGENTS”, outlines compositions and methods for
generating antibodies to neutralize SARS-CoV-2 (the coronavirus
causing COVID-19) using computer-based simulation technology. Such
antibodies are envisioned to prevent and treat the life-threatening
symptoms of COVID-19. The use of computer simulation creates highly
targeted antibodies by improving pre-existing antibodies. The
improvements include, but are not limited to, creating higher
affinity and/or specificity antibodies to the SARS-CoV-2 Spike
protein (the protein which the virus uses to infect cells) versus
the unmodified antibody. The resulting therapeutic antibodies are
expected to quickly and specifically recognize the SARS-CoV-2
virus, bind to it, and neutralize it. The patent application also
provides compositions and methods, using similar technologies, for
cancer-directed antibodies.
Separately, BriaCell announced on April 14, 2020
(link) the filing of a coronavirus immunotherapy patent, which
expands on the clinical applications of BriaCell’s whole-cell
immunotherapies to those of infectious diseases including the
SARS-CoV-2 virus.
BriaCell has filed in April 2020 two distinct
yet complimentary provisional patent applications related to 1)
Immunotherapy and 2) Antibody-Based
Treatment, outlined as follows:
Patent Application 1 (April 14, 2020 press
release): Immunotherapy Approach
- “INDUCING IMMUNE RESPONSES BY TRANSFORMING CANCER CELLS INTO
ANTIGEN-PRESENTING CELLS”;
- Based on molecular analyses of BriaCell’s whole-cell
immunotherapy anti-tumor product candidate, designed to stimulate
the immune system to recognize and destroy the patient’s tumors by
acting as antigen-presenting cells.
Patent Application 2 (April 21, 2020 press release):
Antibody-Based Treatment Approach
- “COMPUTER-GUIDED DESIGN OF ANTIBODIES INCLUDING NEUTRALIZING
SARS-CoV-2 BINDING AGENTS”;
- Antibodies designed and selected to neutralize SARS-CoV-2 using
computer simulation – envisioned to prevent and treat the
life-threatening symptoms of COVID-19;
- BriaCell hypothesizes that antibodies may quickly and
specifically recognize the SARS-CoV-2 virus, bind to it, and
neutralize it.
The patent application seeks protection for the
design of new therapeutic antibodies and methods for their use.
The Company cautions that COVID-19 therapeutic
development is still under early-stage research and development and
is not making any express or implied claims that it has the ability
to treat, prevent or eliminate the COVID-19 virus at this time.
The Company’s scientific experts have read and
approved the scientific disclosures contained in the press
release.
About Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019, abbreviated as
COVID-19, refers to a new disease, caused by a novel (or new)
coronavirus that has not previously been seen in humans. The novel
coronavirus is also called severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2; previously known as 2019-nCoV).
The clinical spectrum of SARS-CoV-2 infection appears to be
wide, ranging from asymptomatic infection, and mild upper
respiratory tract illness to severe viral pneumonia with
respiratory failure and even death, with many patients being
hospitalized with pneumonia.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024